Journal article
CML biology for the clinician in 2011: six impossible things to believe before breakfast on the way to cure
Abstract
Chronic myeloid leukemia (cml) is a model disease in oncology: it is the first human cancer linked to a distinct chromosomal abnormality, ultimately causing constitutive overactivity of a known oncogenic tyrosine kinase that represents a drug target. The introduction of the tyrosine kinase inhibitor imatinib into clinical practice has far exceeded expectations and resurrected hope that the fundamental insights from the "war on cancer" can lead …
Authors
Leber B
Journal
Current Oncology, Vol. 18, No. 4, pp. 185–190
Publisher
MDPI
Publication Date
August 2011
DOI
10.3747/co.v18i4.652
ISSN
1198-0052